Sickle cell disease can be deadly, and the persistent health inequities facing Black Americans worsen the problem

For patients with sickle cell disease, about half of their blood cells have the characteristic sickle shape, preventing proper blood flow and oxygen from getting to organs and tissues. Mark Garlick/Science Photo Library via Getty Images^[9]

A reduced life expectancy

Worldwide, nearly 8 million people live with sickle cell disease^[10]. In the U.S., 100,000 people have the disease. Three million more Americans carry the sickle cell gene, a condition known as sickle cell trait^[11], because they inherited the gene from only one parent.

Most ancestors of those with sickle cell trait likely came from Africa, South Asia or Mediterranean regions where it protected the population against malaria^[12]. When the malaria parasite infects the red blood cells of someone with sickle cell trait, the infected cell sickles, and then the body’s immune system removes^[13] it.

Sickle cell disease is particularly devastating to families in lower-income countries, where many children with the condition die before their fifth birthday^[14]. In contrast, few American children with sickle cell disease who have access to medical care die during childhood.

Still, life expectancy for those with sickle cell disease in the U.S., even with public health insurance, is almost 24 years less^[15] than the general population – 52.6 years compared with 76.1 years^[16].

Health inequities

Of the nearly 75,000 Americans hospitalized for sickle cell disease from 2016 to 2018, more than 93% were Black^[17]. A century after sickle cell disease was identified^[18], glaring health inequities^[19] in its diagnosis, treatment, cures and research about it persist. Although anyone with a faulty hemoglobin gene can pass the disease to their children, in the U.S. it is most common in those of African descent. Structural racism and stigma compound the inequities.

People with the disease frequently visit the emergency room and are hospitalized for pain control. Sometimes, these acute pain episodes are excruciating and last up to 11 days^[20]. But often, doctors and nurses do not believe their complaints^[21] and requests for strong medications to stop the pain. Instead, they may suspect drug-seeking behavior, deny them pain medicines and label them drug addicts.

These negative views stigmatize those with the disease and contribute to the stress of living with the illness. Patients report feeling “less than human” when providers ignore or discount their pain complaints^[22].

As a result, many patients with sickle cell disease avoid going to the emergency room and do so only when they have exhausted every treatment available at home. They wait, as the pain intensifies to 8, 9 or 10 on a 0-10 scale. By remaining at home, not only is the patient enduring unremitting pain, they are also delaying treatment for organ and tissue damage caused by the disease.

A bone marrow transplant is one of the possible cures for sickle cell disease.

Treatments, cures and hope

In my view, better dialogue between patients, families and providers is critical. A communications tool called the situation, background, assessment, recommendation communication method^[23] could help patients when interacting with providers^[24] about their pain and, over time, reduce stigma associated with the illness.

Some adults may have been tested for sickle cell trait as newborns but were not told or do not remember whether they have it. These adults are unaware of their risk for having a baby with the disease. This is why testing, along with genetic counseling, is also critical^[25].

Today in the U.S., all newborn babies are now tested^[26] for both sickle cell disease and sickle cell trait. This test helps to spot and treat the disease early, before the baby has symptoms or serious problems, and reduces one structural racism contributor because every baby is tested.

Red blood cell transfusions are an important and lifesaving treatment^[27] for sickle cell disease. But there are challenges to transfusion therapy, including difficulty getting into a vein, iron overload, reactions to the transfusion and the time commitment and travel expenses.

Treatment with daily oral hydroxyurea is the standard of care for prevention of pain^[28] in both children and adults with sickle cell. This drug increases fetal hemoglobin, which reduces red blood cell sickling. There are also other drugs available that can reduce red blood cell sickling.

One therapy that can cure sickle cell disease is hematopoietic stem cell transplantation^[29]. This is the transfer of stem cells capable of making normal blood cells to replace the sickle cells. The stem cells are transplanted to the patient from a well-matched sibling, which limits who can get them.

Since 1984, 1,200 hematopoietic stem cell transplantation cases have been reported^[30]. However, the treatment can have serious toxicities, fatal complications, effects on fertility and significant financial costs that must be weighed against the severity of the disease.

Other cures are gene therapies to repair the faulty hemoglobin gene so that it no longer makes sickle red blood cells^[31]. But gene therapy is not yet a standard cure.

Neither of these curative treatments alters the genes in the ovum or sperm, so the patient’s future children are still at risk of inheriting the disease.

A future with health equity for sickle cell disease is possible, but only when pain is controlled and treatments have fewer complications and can be made affordable everywhere.

Authors: Diana J. Wilkie, Professor of Nursing, University of Florida

Read more https://theconversation.com/sickle-cell-disease-can-be-deadly-and-the-persistent-health-inequities-facing-black-americans-worsen-the-problem-212434

• Prev
• Next